116TH CONGRESS
1ST SESSION **H. R. 4144**

To enable States to better provide access to whole genome sequencing clinical
    services for certain undiagnosed children under the Medicaid program,
    and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

AUGUST 2, 2019

Mr. PETERS (for himself, Mr. SHIMKUS, and Mr. VARGAS) introduced the
following bill; which was referred to the Committee on Energy and Commerce

A BILL

To enable States to better provide access to whole genome
    sequencing clinical services for certain undiagnosed chil-
    dren under the Medicaid program, and for other pur-
    poses.

1   *Be it enacted by the Senate and House of Representa-*

2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4   This Act may be cited as the "Ending the Diagnostic

5 Odyssey Act of 2019".

SEC. 2. STATE OPTION TO PROVIDE WHOLE GENOME SE-QUENCING CLINICAL SERVICES FOR CER-TAIN CHILDREN.

Title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) is amended by inserting after section 1943 the following new section:

"SEC. 1944. STATE OPTION TO PROVIDE WHOLE GENOME SEQUENCING CLINICAL SERVICES FOR CER-TAIN CHILDREN.

"(a) IN GENERAL.—Notwithstanding section 1902(a)(1) (relating to statewideness), section 1902(a)(10)(B) (relating to comparability), and any other provision of this title for which the Secretary determines it is necessary to waive in order to implement this section, beginning January 1, 2020, a State, at its option as a State plan amendment, may provide for medical assistance under this title to an eligible individual for purposes of providing the individual with whole genome sequencing clinical services.

"(b) PAYMENTS.—

"(1) IN GENERAL.—A State shall provide a health care provider (as defined by the State) with payments for the provision of whole genome sequenc-ing clinical services to any eligible individual. Pay-ments made to a health care provider for such serv-ices shall be treated as medical assistance for pur-

1 poses of section 1903(a), except that, during the

2 first 12 fiscal year quarters that the State plan

3 amendment is in effect, the Federal medical assist-

4 ance percentage applicable to such payments shall be

5 equal to 75 percent.

6 ''(2) METHODOLOGY.—The State shall specify

7 in the State plan amendment the methodology the

8 State will use for determining payment for the provi-

9 sion of whole genome sequencing clinical services.

10 Such methodology for determining payment shall be

11 established consistent with section 1902(a)(30)(A).

12 ''(3) PLANNING GRANTS.—

13 ''(A) IN GENERAL.—Beginning January 1,

14 2020, the Secretary may award planning grants

15 to States for purposes of developing a State

16 plan amendment under this section. A planning

17 grant awarded to a State under this paragraph

18 shall remain available until expended.

19 ''(B) STATE CONTRIBUTION.—A State

20 awarded a planning grant shall contribute an

21 amount equal to the State percentage deter-

22 mined under section 1905(b) for each fiscal

23 year for which the grant is awarded.

24 ''(c) HOSPITAL REFERRALS.—A State shall include

25 in the State plan amendment a requirement for any hos-

1 pital that is a participating provider under the State plan

2 (or a waiver of such plan) to establish procedures for re-

3 ferring any eligible individual who seeks or needs treat-

4 ment in a hospital emergency department to a health care

5 provider who is qualified (as determined by the State) to

6 provide whole genome sequencing clinical services.

7   ''(d) REPORTS BY STATES.—Not later than 3 years

8 after the date on which the State plan amendment under

9 this section is approved, a State shall submit a report to

10 the Administrator of the Centers for Medicare & Medicaid

11 Services and the Administrator of the Health Resources

12 and Services Administration on—

13   ''(1) the extent to which whole genomic se-

14   quencing clinical services reduce health disparities;

15   and

16   ''(2) the extent to which coverage under the

17   State plan (or a waiver of such plan) impedes the

18   use of genetic and genomic testing that may improve

19   clinical outcomes for eligible individuals enrolled in

20   the State plan (or under a waiver of such plan).

21   ''(e) REPORTS BY HEALTH CARE PROVIDERS.—As a

22 condition for receiving payment for whole genome sequenc-

23 ing clinical services provided to an eligible individual, a

24 health care provider shall report to the State, in accord-

25 ance with such requirements as the Secretary shall specify,

5

1 on all applicable measures for determining the quality of

2 such services.

3   "(f) DEFINITIONS.—In this section:

4   "(1) ELIGIBLE INDIVIDUAL.—The term 'eligible

5   individual' means an individual—

6   "(A) who is eligible for medical assistance

7   under the State plan (or a waiver of such plan);

8   "(B) who is under the age of 21 (or, at the

9   option of the State, under the age of 20, 19, or

10   18 as the State may choose), or in the case of

11   an individual described in section

12   1902(a)(10)(A)(i)(IX), under the age of 26;

13   and

14   "(C) who—

15   "(i) has been referred or admitted to

16   an intensive care unit, or has been seen by

17   at least one medical specialist, for a sus-

18   pected genetic or undiagnosed disease; or

19   "(ii) is suspected by at least one med-

20   ical specialist to have a neonatal- or pedi-

21   atric-onset genetic disease.

22   "(2) WHOLE GENOME SEQUENCING CLINICAL

23   SERVICES.—The term 'whole genome sequencing

24   clinical services', with respect to an eligible indi-

25   vidual—

1   ''(A) means the unbiased sequencing of all

2   deoxyribonucleic acid bases in the genome of

3   such individual and, if for the sole benefit of

4   the individual, a biological parent of such indi-

5   vidual for the purpose of determining whether

6   one or more potentially disease-causing genetic

7   variants are present in the genome of such indi-

8   vidual or such biological parent; and

9   ''(B) includes any analysis, interpretation,

10   and data report derived from such sequenc-

11   ing.''.

○